Finn Anastasia, Bondarenka Carolyn, Edwards Kathy, Hartwell Rebekah, Letton Cathy, Perez Andy
Department of Pharmacy, Medical University of South Carolina, Charleston, SC, USA.
J Oncol Pharm Pract. 2017 Dec;23(8):563-574. doi: 10.1177/1078155216665247. Epub 2016 Aug 29.
Background With the ever growing arsenal of oral chemotherapy agents now available, cancer treatment is being increasingly managed in the outpatient setting. However, oral chemotherapy use is often associated with several potential obstacles and complications. In order to provide optimal patient safety and oral chemotherapy monitoring, our institution implemented an oral chemotherapy program managed by clinical pharmacists electronically through Epic Beacon. Objective To describe implementation of a novel pharmacist-managed oral chemotherapy program and evaluate pharmacist interventions before and after implementation of an oral chemotherapy program. Methods This was a single-center retrospective chart review of documented pharmacy interventions for oral chemotherapy prescriptions during three months prior to as well as three months following Epic Beacon implementation. Time periods for data inclusion were October-December 2013 (pre-Beacon) and October-December 2014 (post-Beacon). Patients included in the study had one or more oral chemotherapy orders during the pre-Beacon period, the post-Beacon period, or both pre- and post-Beacon. Our analysis did not include oral chemotherapy orders that were placed outside of a treatment plan in the post-Beacon period. Results A total of 240 patients with 450 total oral chemotherapy orders were assessed over the duration of the study. Beacon implementation allowed a greater number of oral chemotherapy orders to be reviewed, with 134 oral chemotherapy orders reviewed in the study period prior to Beacon implementation and 316 orders reviewed in the post-Beacon period. Additionally, there were 660% more pharmacist interventions (89 interventions pre-Beacon versus 681 interventions post-Beacon), with an increased focus on coordination of care, chemotherapy calendar coordination, and assistance with treatment plans. Furthermore, implementation of Epic Beacon allowed identification of over 500% more chemotherapy order errors (41 total errors identified pre-Beacon versus 250 total errors identified post-Beacon). Pharmacists were also able to identify more significant, serious, or potentially lethal errors following implementation. The time associated with oral chemotherapy review and intervention also increased accordingly with number of orders reviewed. Conclusion Implementation of an electronic workflow for oral chemotherapy dramatically increased pharmacist review of orders, resulting in improved documentation of interventions and errors, decreased need for clarification of orders, as well as increased volume of prescriptions at our on-site pharmacy. This study demonstrates a comprehensive approach to maximize safety when oral chemotherapy is utilized as a component of the treatment regimen.
背景 随着现有口服化疗药物种类的不断增加,癌症治疗越来越多地在门诊环境中进行管理。然而,口服化疗的使用常常伴随着一些潜在的障碍和并发症。为了确保患者的最佳安全并对口服化疗进行监测,我们机构实施了一项由临床药师通过Epic Beacon电子管理的口服化疗项目。目的 描述一项由药师管理的新型口服化疗项目的实施情况,并评估口服化疗项目实施前后药师的干预措施。方法 这是一项单中心回顾性图表审查,涉及Epic Beacon实施前三个月以及实施后三个月期间口服化疗处方的药学干预记录。纳入数据的时间段为2013年10月至12月(Beacon实施前)和2014年10月至12月(Beacon实施后)。纳入研究的患者在Beacon实施前、Beacon实施后或前后两个时间段都有一项或多项口服化疗医嘱。我们的分析不包括Beacon实施后超出治疗计划开具的口服化疗医嘱。结果 在研究期间,共评估了240例患者的450份口服化疗医嘱。Beacon的实施使得更多的口服化疗医嘱得到审查,在Beacon实施前的研究期间审查了134份口服化疗医嘱,在Beacon实施后审查了316份医嘱。此外,药师的干预增加了660%(Beacon实施前89次干预,Beacon实施后681次干预),并且更加注重护理协调、化疗日程协调以及治疗计划协助。此外,Epic Beacon的实施使得识别出的化疗医嘱错误增加了500%以上(Beacon实施前共识别出41处错误,Beacon实施后共识别出250处错误)。实施后,药师还能够识别出更多重大、严重或潜在致命的错误。与口服化疗审查和干预相关的时间也随着审查的医嘱数量相应增加。结论 口服化疗电子工作流程的实施显著增加了药师对医嘱的审查,从而改善了干预措施和错误的记录,减少了医嘱澄清的需求,并增加了我们现场药房的处方量。本研究展示了一种在将口服化疗用作治疗方案组成部分时最大化安全性的综合方法。